CSF2 and melanoma: Finally, we identified a clinical trial combining a long peptide vaccine with the anti-PD-1 molecule toripalimab and granulocyte macrophage-colony stimulating factor (GM-CSF) in melanoma; however, no additional information is available concerning this trial or vaccine (NCT04072900).